<DOC>
	<DOCNO>NCT00570193</DOCNO>
	<brief_summary>The goal pilot study validate use combination Lucentis ( ranibizumab ) Visudyne ( verteporfin ) treatment choroidal neovascularization ( CNV ) secondary age-related macular degeneration ( AMD ) explore use volumetric analysis CNV lesion determine disease activity , response therapy , tool determine need retreatment .</brief_summary>
	<brief_title>Photodynamic Pharmacologic Treatment CNV</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>All previously untreated CNV secondary MD</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>